Morning Watchlist: Wednesday Edition
A quick note from Behind the Markets
It's the middle of the week, and Tuesday turned out to be report-card day for everybody at once: four of the biggest banks handed in earnings, so did the biggest health insurer, and — nobody had this on the calendar — the global memory-chip industry got graded by a press release from China.
One more test lands this morning: the September inflation report, at 8:30, minutes before this note reaches you. Our cheat sheet, written before the number printed, waits in Before You Go.
Three stories this morning. Three pairings. Let's get into it.
1) The Banks Confessed. The Consumer Passed.
On Sunday we said the first page we'd read in the bank reports was provisions — whether September's 29,000-job stumble had banks bracing for loans that won't come back. Tuesday's early answer: not yet. Wells Fargo earned $1.87 a share, up from $1.66 a year ago, and said its customers were doing well despite economic uncertainty. JPMorgan posted a rare miss — $5.57 a share against the $5.90 expected, dented by $658 million of losses on repositioned investment securities — and the stock rose about 1% anyway, with Jamie Dimon calling the economy strong while warning of risks "shifting under the surface."
And our October 2nd Goldman Sachs Buy took its first exam. It passed with room to spare: earnings of $17.01 a share against roughly $13 expected, revenue up 23%, and an equities-trading haul up 72% to $6.4 billion — the auction house we bought for the fees got paid at every table in the building. The honest footnotes: the investment-banking backlog slipped from last quarter, and the early pop to about $908 still sits a touch below our $916 flag. The thesis was the cycle, not the quarter. Tuesday, the cycle showed up. Still Buy.
So the banks that see America's paychecks first say the paychecks still clear. One company's entire business is that sentence.
The pairing: Synchrony Financial (SYF) — Buy
Synchrony runs the tab. It's the bank behind the store card at thousands of retailers — and behind CareCredit at the dentist and the vet — the bartender who knows every regular's tab and charges accordingly: its net interest margin last quarter was 15%. Purchase volume hit a record $49.8 billion, and the number that matters most moved the right way: loans written off fell to 5.43% of the book from 5.70% a year earlier.
At Monday's close of $73.62, this $24 billion lender costs about 7.8 times this year's guided earnings. The S&P 500: 21 times. Twenty-four analysts say Buy with an average target near $88, yet the target-cutters have been busy into next Tuesday's report — nervous about exactly the credit question the banks just answered benignly. We bought auto lender Ally on September 30th; Synchrony is the shopping-cart side of the same consumer. And yes, on Sunday we bought Encore, the junkyard that buys the loans banks give up on. The middle of the road pays both: a tired consumer who keeps paying. The kill, same as Ally's: the labor market actually breaking — a 15%-margin lender is only cheap if the regulars keep their jobs.
2) Black Tuesday in Seoul
Over the weekend, at an industry event in Shanghai, the president of ChangXin Memory Technologies — CXMT, China's biggest DRAM maker — claimed "key progress" on a denser memory-cell design and said a server memory product built on it arrives by year-end.
The market's response was not calm. Samsung fell 4.4% Monday and another 7.4% Tuesday. SK Hynix fell 4.5%, then 10.1% — Seoul's papers called it Black Tuesday, and the KOSPI sank more than 4%, tripping a trading curb. Micron, our September 15th Buy, slipped about 3.9% Monday to near $989 and opened lower Tuesday. Broadcom's Hock Tan picked the same week to compare AI investing to a casino and warn that "access to capital could become one of the biggest constraints on AI growth" — the creak we've tracked since Oracle's September notice.
Now the other column. The Wall Street Journal reports CXMT still trails Samsung, SK Hynix, and Micron by two to three generations. And when Apple reportedly explored buying CXMT memory in July, it balked — because CXMT wanted prices above the incumbents'. A company charging more than Samsung is not yet the discounter that breaks the market. We graded Embraer on this rule in September: a press release is not a product. Micron's kill switch is DRAM contract prices actually cracking; a claim from a rival two generations back, against $150 billion of Micron revenue already under defined-price contracts, isn't that. Still roughly 7% above our flag — still Buy. (Our equipment Watches, Lam Research and Entegris, drift toward their named entrances on days like this. Neither printed. We wait.)
But here's the step behind the headline. The market spent two days repricing every flour mill on Earth because China promised to open a new one. Nobody walked across the street to reprice the bakery.
The pairing: HP Inc. (HPQ) — Watch
HP buys more memory than almost anyone alive — every PC it ships carries DRAM and storage, and that bill is the whole problem: memory costs roughly doubled this year (Intel's CEO says prices run "5 to 7 times their previous levels"), and in September HP took the rare step of withholding fiscal 2027 guidance, warning PC volumes could fall mid-single digits as the memory bill forces prices up. That's why a $27 billion franchise trades at about 10 times next year's expected earnings with a 4% dividend, at $29.87 against a 52-week high of $36.
Every new DRAM supplier on Earth is a free option on HP's cost line. So why Watch and not Buy? Because the relief is a press release and the squeeze is an invoice. The entrance: DRAM contract prices actually rolling over, or the November 24th report showing HP's price hikes sticking without killing demand. The kill: memory at famine prices through 2027 while PC volumes fall — a bakery squeezed at both doors. The honest flag: the average analyst target sits at the price. Nobody's arguing for it yet. That's usually when we start watching.
3) The Insurer Walked Out of the Recovery Ward
The whole health-insurance aisle caught the same flu two years ago — medical costs running hotter than the premiums priced to cover them. On Tuesday, the biggest patient discharged itself. UnitedHealth earned $4.69 a share against the $4.12 expected, and the number underneath was the cure in print: 88.4 cents of every premium dollar went out as medical costs, when Wall Street expected 89.9. The full-year forecast rose to at least $20.50 a share, and the stock rose about 3% in early trading.
Housekeeping first: Tenet, Sunday's hospital Buy, carried the named risk that the landlord would blame the heating bill on Tuesday's call. No complaint landed — the insurer beat while the hospitals' receipts stay strong. Tenet reports October 29th. Still Buy.
The fresh idea is one aisle over. Aetna caught the same flu as UnitedHealth, later — and Aetna belongs to CVS.
The pairing: CVS Health (CVS) — Buy
CVS is the drugstore on every corner that also owns a top-three insurer, and it's running the exact repair UnitedHealth just validated: reprice the premiums, wait for the medical-cost fever to pass. The repair is working — adjusted earnings rose 40% last quarter, every segment outperformed, the full-year forecast was raised — yet at Monday's close of $87.74 the company costs about 10.8 times next year's expected earnings, roughly half UnitedHealth's multiple and half the S&P's 21. A 3% dividend pays the wait. Twenty-seven analysts call it a Strong Buy, average target near $115.
Why the fresh discount? Medicare's new 2027 star ratings dinged Aetna last week — the share of members in four-star-plus plans slipped to about 69% — and star ratings feed the bonus checks Medicare writes in 2028. That's a real bill, and it's the kill if the ratings slide becomes a membership slide. Add the usual capitol-building risks every insurer carries — and note the trailing P/E of 23 is merger-and-writedown noise; use the forward number — and you have a turnaround priced like a relapse, the week the aisle's biggest name proved the medicine works. CVS reports November 4th.
Before You Go
That's the watchlist. The banks said the paychecks still clear, Seoul burned its mills over a Chinese press release, and the insurance ward's biggest patient walked out — with the tab-keeper, the bakery, and the drugstore standing one step behind those headlines.
Now, this morning's inflation report. The cheat sheet we wrote going in: forecasters expected the headline near 3.6% to 3.7%, pushed up almost entirely by war-priced energy, with core near 2.4%. A hot core number puts the Fed's penciled-in hike back on the table for October 27–28 and re-marks everything that borrows; a cool one leaves the bond market arguing about supply, not the Fed. Bank of America and Morgan Stanley also report this morning, and ASML opens the chip-equipment confessional. Thursday brings TSMC's full report, producer prices, and retail sales, plus Schwab and U.S. Bancorp. And oil eased Tuesday — WTI near $92 as Washington's Russian-diesel license took effect — while fresh Houthi attacks on Saudi Arabia reminded everyone why the war premium exists at all.
Found this helpful? Share it with others.
Written by Behind the Markets